Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Ivosidenib is an oral inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, approved for treatment of IDH1-mutant (mIDH1) acute myeloid leukemia (AML). Preclinical work suggested that addition of azacitidine to ivosidenib enhances mIDH1 inhibition–related differentiation and apoptosis. P...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Clin Oncol
Main Authors: DiNardo, Courtney D., Stein, Anthony S., Stein, Eytan M., Fathi, Amir T., Frankfurt, Olga, Schuh, Andre C., Döhner, Hartmut, Martinelli, Giovanni, Patel, Prapti A., Raffoux, Emmanuel, Tan, Peter, Zeidan, Amer M., de Botton, Stéphane, Kantarjian, Hagop M., Stone, Richard M., Frattini, Mark G., Lersch, Frederik, Gong, Jing, Gianolio, Diego A., Zhang, Vickie, Franovic, Aleksandra, Fan, Bin, Goldwasser, Meredith, Daigle, Scott, Choe, Sung, Wu, Bin, Winkler, Thomas, Vyas, Paresh
格式: Artigo
語言:Inglês
出版: American Society of Clinical Oncology 2021
主題:
ORIGINAL REPORTS
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7771719/
https://ncbi.nlm.nih.gov/pubmed/33119479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01632
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍